Inari Medical to Present in Upcoming Investor Conferences

IRVINE, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. NARI ("Inari"), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that its management team will present at the following upcoming investor conferences:

  • The BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, Wednesday, February 17, 2021 at 4:00 p.m. Eastern Time



  • The 2021 SVB Leerink Partners Virtual Global Healthcare Conference, Wednesday, February 24, 2021 at 1:00 p.m. Eastern Time. A live webcast of the presentation may be accessed on the "Investor Relations" section of the company's website at: https://www.inarimedical.com/.

About Inari Medical, Inc.

Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium.

Investor Contact:

Westwicke Partners

Caroline Corner

Phone +1-415-202-5678

caroline.corner@westwicke.com



Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!